New approaches to the development of adenoviral dendritic cell vaccines in melanoma

Current Opinion in Investigational Drugs

Volumn 11, Issue 12, 2010, Pages 1399-1408

  Butterfield, Lisa H ^a   Vujanovic, Lazar ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Adenovirus; cancer vaccine; costimulation; cytokine; dendritic cell; melanoma

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; INTERLEUKIN 12P70; INTERLEUKIN 18; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ADENOVIRUS INFECTION; ADVANCED CANCER; CANCER IMMUNOTHERAPY; CELL FUNCTION; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; GENE EXPRESSION; GENE THERAPY; HUMAN; INNATE IMMUNITY; LYMPHOCYTE; MELANOMA; NONHUMAN; PHENOTYPE; REVIEW; SEROTYPE; SIGNAL TRANSDUCTION; TRANSGENE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CYTOKINES; DENDRITIC CELLS; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; PHENOTYPE; TRANSDUCTION, GENETIC;

EID: 79952769702     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Cancer Facts & Figures. American Cancer Society (2010). www.cancer.org/research/cancerfactsfgures/index
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363(8):711-723.
3. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245-252. (Pubitemid 28155090)
4. Steinman RM, Young JW: Signals arising from antigen-presenting cells. Curr Opin Immunol (1991) 3(3):361-372.
5. Steinman RM, Pack M, Inaba K: Dendritic cell development and maturation. Adv Exp Med Biol (1997) 417:1-6. (Pubitemid 27427711)
6. McColl SR: Chemokines and dendritic cells: A crucial alliance. Immunol Cell Biol (2002) 80(5):489-496.
7. LaSalle JM, Hafer DA: T cell anergy. FASEB J (1994) 8(9):601-608. (Pubitemid 24198677)
8. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med (1996) 183(1):87-97. (Pubitemid 26028748)
9. Porgador A, Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med (1995) 182(1):255-260.
10. Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M: Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol (1994) 24(3):605-610. (Pubitemid 24076623)
11. Timmerman JM, Levy R: Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med (1999) 50:507-529. (Pubitemid 29117080)
12. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 2(1):52-58. (Pubitemid 26028073)
13. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med (1998) 4(3):328-332. (Pubitemid 28144092)
14. Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Bröcker EB et al: Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specifc cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med (1999) 190(11) 1669-1678. (Pubitemid 30002348)
15. Butterfeld LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ et al: Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res (2003) 9(3):998-1008. (Pubitemid 36323703)
16. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN et al: Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother (2004) 27(5):354-367. (Pubitemid 39121924)
17. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM: Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: Assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother (2009) 58(1): 1-14.
18. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med (2004) 10(9):909-915. (Pubitemid 39273730)
19. Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, Blanck JP, Johnston DA, Palucka AK, Fay J: Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother (2005) 28(5):505-516. (Pubitemid 41232572)
20. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P: α-Type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 64(17): 5934-5937. (Pubitemid 39129387)
21. Campos SK, Barry MA: Current advances and future challenges in adenoviral vector biology and targeting. Curr Gene Ther (2007) 7(3):189-204. (Pubitemid 46902201)
22. Ribas A, Butterfeld LH, McBride WH, Dissette VB, Koh A, Vollmer CM, Hu B, Chen AY, Glaspy JA, Economou JS: Characterization of antitumor immunization to a defned melanoma antigen using genetically engineered murine dendritic cells. Cancer Gene Ther (1999) 6(6):523-536. (Pubitemid 129667827)
23. Ribas A, Butterfeld LH, McBride WH, Jilani SM, Bui LA, Vollmer CM, Lau R, Dissette VB, Hu B, Chen AY, Glaspy JA et al: Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res (1997) 57(14):2865-2869. (Pubitemid 27315029)
24. Lindsay RW, Darrah PA, Quinn KM, Wille-Reece U, Mattei LM, Iwasaki A, Kasturi SP, Pulendran B, Gall JG, Spies AG, Seder RA: CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. J Immunol (2010) 185(3): 1513-1521.
25. Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ: Identifcation of a conserved receptor-binding site on the fber proteins of CAR-recognizing Adenoviridae. Science (1999) 286(5444):1568-1571.
26. v integrins in adenovirus cell entry and gene delivery. Microbiol Mol Biol Rev (1999) 63(3):725-734. (Pubitemid 29422788)
27. vβ5 promote adenovirus internalization but not virus attachment. Cell (1993) 73(2):309-319. (Pubitemid 23123309)
28. Perreau M, Mennechet F, Serratrice N, Glasgow JN, Curiel DT, Wodrich H, Kremer EJ: Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: Implications for clinical effcacy. J Virol (2007) 81(7):3272-3284. (Pubitemid 46456636)
29. Tillman BW, de Gruijl TD, Luykx-de Bakker SA, Scheper RJ, Pinedo HM, Curiel TJ, Gerritsen WR, Curiel DT: Maturation of dendritic cells accompanies high-effciency gene transfer by a CD40-targeted adenoviral vector. J Immunol (1999) 162(11):6378-6383. (Pubitemid 29309357)
30. Cheng C, Gall JG, Kong WP, Sheets RL, Gomez PL, King CR, Nabel GJ: Mechanism of Ad5 vaccine immunity and toxicity: Fiber shaft targeting of dendritic cells. PLoS Pathog (2007) 3(2):e25.
31. Arthur JF, Butterfeld LH, Roth MD, Bui LA, Kiertscher SM, Lau R, Dubinett S, Glaspy J, McBride WH, Economou JS: A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther (1997) 4(1):17-25. (Pubitemid 127672232)
32. Nociari M, Ocheretina O, Schoggins JW, Falck-Pedersen E: Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. J Virol (2007) 81(8): 4145-4157. (Pubitemid 46586909)
33. Zhu J, Huang X, Yang Y: Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and-independent pathways. J Virol (2007) 81(7):3170-3180. (Pubitemid 46456626)
34. Tan PH, Beutelspacher SC, Xue SA, Wang YH, Mitchell P, McAlister JC, Larkin DF, McClure MO, Stauss HJ, Ritter MA, Lombardi G et al: Modulation of human dendritic cell function following transduction with viral vectors: Implications for gene therapy. Blood (2005) 105(10):3824-3832. (Pubitemid 40656124)
35. Butterfeld LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B et al: Generation of melanoma-specifc cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol (1998) 161(10):5607-5613. (Pubitemid 28519126)
36. Diao J, Smythe JA, Smyth C, Rowe PB, Alexander IE: Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. Gene Ther (1999) 6(5):845-853. (Pubitemid 29243659)
37. Lundqvist A, Choudhury A, Nagata T, Andersson T, Quinn G, Fong T, Maitland N, Pettersson S, Paulie S, Pisa P: Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis. Hum Gene Ther (2002) 13(13):1541-1549. (Pubitemid 35034674)
38. Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, Butterfeld LH: Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specifc T-cell responses. J Immunother (2004) 27(3):191-200. (Pubitemid 39118083)
39. Vujanovic L, Whiteside TL, Potter DM, Chu J, Ferrone S, Butterfeld LH: Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunol Immunother (2009) 58(1):121-133.
40. Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL, Butterfeld LH: Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood (2010) 116(4):575-583.
41. Smith CA, Woodruff LS, Kitchingman GR, Rooney CM: Adenovirus-pulsed dendritic cells stimulate human virus-specifc T-cell responses in vitro. J Virol (1996) 70(10):6733-6740. (Pubitemid 26307380)
42. Roth MD, Cheng Q, Harui A, Basak SK, Mitani K, Low TA, Kiertscher SM: Helper-dependent adenoviral vectors effciently express transgenes in human dendritic cells but still stimulate antiviral immune responses. J Immunol (2002) 169(8):4651-4656. (Pubitemid 35178246)
43. Gahéry-Ségard H, Molinier-Frenkel V, Le Boulaire C, Saulnier P, Opolon P, Lengagne R, Gautier E, Le Cesne A, Zitvogel L, Venet A, Schatz C et al: Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest (1997) 100(9):2218-2226. (Pubitemid 27500144)
44. Meng WS, Butterfeld LH: Activation of antigen-presenting cells by DNA delivery vectors. Expert Opin Biol Ther (2005) 5(8):1019-1028. (Pubitemid 41170032)
45. Grabski E, Waibler Z, Schüle S, Kloke BP, Sender LY, Panitz S, Cichutek K, Schweizer M, Kalinke U: Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems. Mol Biotechnol (2010):doi:10.1007/s12033-010-9340.
46. Negri DR, Bona R, Michelini Z, Leone P, Macchia I, Klotman ME, Salvatore M, Cara A: Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specifc CD8+ T cells. Hum Gene Ther (2010) 21(8):1029-1035.
47. Mobergslien A, Sioud M: Optimized protocols for siRNA delivery into monocytes and dendritic cells. Methods Mol Biol (2010) 629:71-85.
48. Liu Y, Daley S, Evdokimova VN, Zdobinski DD, Potter DM, Butterfeld LH: Hierarchy of α fetoprotein (AFP)-specifc T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol (2006) 177(1):712-721. (Pubitemid 43939186)
49. Perez-Diez A, Butterfeld LH, Li L, Chakraborty NG, Economou JS, Mukherji B: Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res (1998) 58(23):5305-5309. (Pubitemid 28551105)
50. Evdokimova VN, Liu Y, Potter DM, Butterfeld LH: AFP-specifc CD4+ helper T-cell responses in healthy donors and HCC patients. J Immunother (2007) 30(4):425-437. (Pubitemid 46684432)
51. Castellino F, Germain RN: Cooperation between CD4+ and CD8+ T cells: When, where, and how. Annu Rev Immunol (2006) 24:519-540.
52. van Stipdonk MJ, Lemmens EE, Schoenberger SP: Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol (2001) 2(5):423-429. (Pubitemid 33706140)
53. Mehrotra S, Chhabra A, Chakraborty A, Chattopadhyay S, Slowik M, Stevens R, Zengou R, Mathias C, Butterfeld LH, Dorsky DI, Economou JS et al: Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. Immunology (2004) 113(4):472-481. (Pubitemid 39593366)
54. He Y, Zhang J, Mi Z, Robbins P, Falo LD Jr: Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol (2005) 174(6):3808-3817. (Pubitemid 40354094)
55. Metharom P, Ellem KA, Wei MQ: Gene transfer to dendritic cells induced a protective immunity against melanoma. Cell Mol Immunol (2005) 2(4):281-288.
56. Nakamura M, Iwahashi M, Nakamori M, Ueda K, Ojima T, Naka T, Ishida K, Yamaue H: Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: Comparison with immunodominant peptide-pulsed DCs. Oncology (2005) 68(2-3):163-170. (Pubitemid 41158972)
57. Yuan J, Latouche JB, Reagan JL, Heller G, Riviere I, Sadelain M, Young JW: Langerhans cells derived from genetically modifed human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specifc CD8+ cytolytic T lymphocyte responses. J Immunol (2005) 174(2):758-766. (Pubitemid 40094270)
58. Curti A, Pandolf S, Aluigi M, Isidori A, Alessandrini I, Chiodoni C, Testoni N, Colombo MP, Baccarani M, Lemoli RM: Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. Exp Hematol (2005) 33(12):1521-1530. (Pubitemid 41773852)
59. van Leeuwen EB, Cloosen S, Senden-Gijsbers BL, Germeraad WT, Bos GM: Transduction with a fber-modifed adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC Cytotherapy (2006) 8(1):36-46. (Pubitemid 43285105)
60. Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T, Storkus WJ: Dendritic cell/peptide cancer vaccines: Clinical responsiveness and epitope spreading. Immunol Invest (2000) 29(2):121-125. (Pubitemid 30316952)
61. Jäger E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jäger D, Oesch F, Knuth A: Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer (1997) 71(2):142-147. (Pubitemid 27252981)
62. Hicklin DJ, Dellaratta DV, Kishore R, Liang B, Kageshita T, Ferrone S:-microglobulin gene mutations in human melanoma cells: Molecular characterization and implications for immune surveillance. Melanoma Res (1997) 7(Suppl 2): S67-S74. (Pubitemid 27501628)
63. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S: Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: Association with disease progression. Am J Pathol (1999) 154(3):745-754. (Pubitemid 29122593)
64. Kamarashev J, Ferrone S, Seifert B, Boni R, Nestle FO, Burg G, Dummer R: TAP1 down-regulation in primary melanoma lesions: An independent marker of poor prognosis. Int J Cancer (2001) 95(1):23-28.
65. Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutter G, Drexler I, Huber C, Ferrone S: Immune escape of melanoma: First evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res (2001) 61(24):8647-8650. (Pubitemid 34013870)
66. Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW et al: Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol (2005) 174(11):6863-6871. (Pubitemid 40705650)
67. Jäger E, Maeurer M, Höhn H, Karbach J, Jäger D, Zidianakis Z, Bakhshandeh-Bath A, Orth J, Neukirch C, Necker A, Reichert TE et al: Clonal expansion of Melan A-specifc cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer (2000) 86(4):538-547. (Pubitemid 30249736)
68. Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA, Haluska FG: Hypopigmentation associated with an adenovirus-mediated gp100/MART-1- transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol (2002) 138(6):799-802. (Pubitemid 34625525)
69. Haluska F, Linette, G, Jonash, S, Hodi S, Longerich S, Yang S, Webb I, Stowell C, Kaplan J, Roberts B, Goldberg M: Immunologic gene therapy of melanoma: Phase I study of therapy with dendritic cells transduced with recombinant adenoviruses encoding melanoma antigens. Proc Am Soc Clin Oncol (2000) 19:453a.
70. Butterfeld LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA et al: Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother (2008) 31(3):294-309. (Pubitemid 351441001)
71. Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfeld LH, Economou JS, Ribas A: Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen- engineered dendritic cells. Cancer Gene Ther (2005) 12(6):516-527. (Pubitemid 40686592)
72. Hart DN: Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood (1997) 90(9):3245-3287. (Pubitemid 27473395)
73. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L: Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med (1999) 5(4):405-411. (Pubitemid 29180578)
74. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G: Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med (2002) 195(3):327-333. (Pubitemid 34461490)
75. Piccioli D, Sbrana S, Melandri E, Valiante NM: Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med (2002) 195(3):335-341. (Pubitemid 34461491)
76. p30 receptor by activated NK cells. J Exp Med (2002) 195(3):343-351. (Pubitemid 34461492)
77. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale M: NK cells and cancer. J Immunol (2007) 178(7):4011-4016. (Pubitemid 46492347)
78. Tourkova IL, Yurkovetsky ZR, Gambotto A, Makarenkova VP, Perez L, Balkir L, Robbins PD, Shurin MR, Shurin GV: Increased function and survival of IL-15-transduced human dendritic cells are mediated by up-regulation of IL-15R and Bcl-2. J Leukoc Biol (2002) 72(5):1037-1045. (Pubitemid 35365179)
79. Kianmanesh A, Hackett NR, Lee JM, Kikuchi T, Korst RJ, Crystal RG: Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor α together with na?ve dendritic cells elicits signifcant suppression of tumor growth without toxicity. Hum Gene Ther (2001) 12(17):2035-2049. (Pubitemid 34053489)
80. Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS, Zeng G, Batra RK, Sharma S, Dubinett SM, Lee JM: Pre-clinical characterization of GMP grade CCL21-gene modifed dendritic cells for application in a phase I trial in non-small cell lung cancer. J Transl Med (2008) 6:38.
81. Vujanovic L, Ranieri E, Gambotto A, Olson WC, Kirkwood JM, Storkus WJ: IL-12p70 and IL-18 gene-modifed dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specifc type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro. Cancer Gene Ther (2006) 13(8):798-805. (Pubitemid 44100493)
82. Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL, Alber SM, Watkins SC, Okada H, Storkus WJ: Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res (2003) 63(19): 6378-6386. (Pubitemid 37255187)
83. Ahn HJ, Maruo S, Tomura M, Mu J, Hamaoka T, Nakanishi K, Clark S, Kurimoto M, Okamura H, Fujiwara H: A mechanism underlying synergy between IL-12 and IFN-inducing factor in enhanced production of IFN-γ. J Immunol (1997) 159(5):2125-2131. (Pubitemid 127681000)
84. Stoll S, Jonuleit H, Schmitt E, Muller G, Yamauchi H, Kurimoto M, Knop J, Enk AH: Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol (1998) 28(10):3231-3239. (Pubitemid 28470269)
85. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A: Interleukin-12: Biological properties and clinical application. Clin Cancer Res (2007) 13(16): 4677-4685. (Pubitemid 47294773)
86. Qin Z, Blankenstein T: CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN receptor expression by nonhematopoietic cells. Immunity (2000) 12(6):677-686.
87. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T: A critical requirement of interferon-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res (2003) 63(14):4095-4100. (Pubitemid 36917932)
88. Appay V: The physiological role of cytotoxic CD4+ T-cells: The holy grail? Clin Exp Immunol (2004) 138(1):10-13. (Pubitemid 39279959)
89. Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM: T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanoma. J Invest Dermatol (1997) 108(6):914-919. (Pubitemid 27272409)
90. Schwaab T, Heaney JA, Schned AR, Harris RD, Cole BF, Noelle RJ, Phillips DM, Stempkowski L, Ernstoff MS: A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon γ and human recombinant interferon 2B therapy in patients with metastatic renal cell carcinoma: Clinical outcome and analysis of immunological parameters. J Urol (2000) 163(4):1322-1327. (Pubitemid 30169433)
91. Wittke F, Hoffmann R, Buer J, Dallmann I, Oevermann K, Sel S, Wandert T, Ganser A, Atzpodien J: Interleukin 10 (IL-10): An immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer (1999) 79(7-8):1182-1184. (Pubitemid 29087895)
92. Okamura H, Kashiwamura S, Tsutsui H, Yoshimoto T, Nakanishi K: Regulation of interferon-production by IL-12 and IL-18. Curr Opin Immunol (1998) 10(3):259-264.
93. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K et al: Cloning of a new cytokine that induces IFN-production by T cells. Nature (1995) 378(6552):88-91.
94. Reddy P: Interleukin-18: Recent advances. Curr Opin Hematol (2004) 11(6):405-410. (Pubitemid 39491434)
95. Gutzmer R, Langer K, Mommert S, Wittmann M, Kapp A, Werfel T: Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J Immunol (2003) 171(12):6363-6371. (Pubitemid 37532063)
96. Kaser A, Kaser S, Kaneider NC, Enrich B, Wiedermann CJ, Tilg H: Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood (2004) 103(2):648-655. (Pubitemid 38140100)
97. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S, Nakanishi K: IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: Synergism with IL-18 for IFN-γ production. J Immunol (1998) 161(7):3400-3407.
98. Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, Hartley SB, Menon S, Kastelein R, Bazan F, O'Garra A: IGIF does not drive Th1 development but synergizes with IL-12 for interferon-production and activates IRAK and NFκB. Immunity (1997) 7(4):571-581. (Pubitemid 27508708)
99. Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD et al: Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res (2002) 8(12):3686-3695. (Pubitemid 35428817)
100. Van Herpen CM, Huijbens R, Looman M, De Vries J, Marres H, Van De Ven J, Hermsen R, Adema GJ, De Mulder PH: Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: A decrease of T-bet in peripheral blood mononuclear cells. Clin Cancer Res (2003) 9(8):2950-2956. (Pubitemid 36993253)
101. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V et al: Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol (2001) 19(18):3836-3847. (Pubitemid 32880062)
102. Van Herpen CM, Looman M, Zonneveld M, Scharenborg N, de Wilde PC, van de Locht L, Merkx MA, Adema GJ, de Mulder PH: Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profle in the locoregional lymph nodes. Clin Cancer Res (2004) 10(8): 2626-2635. (Pubitemid 38509135)
103. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW et al: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 3(3):409-417. (Pubitemid 27158065)
104. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW et al: Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res (2004) 10(16):5432-5438. (Pubitemid 39100480)
105. Mazzolini G, Narvaiza I, Perez-Diez A, Rodriguez-Calvillo M, Qian C, Sangro B, Ruiz J, Prieto J, Melero I: Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. Gene Ther (2001) 8(4):259-267. (Pubitemid 32237058)
106. Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, Ku G, Yu H, Baumann H, Shah MH, Cooper MA, Durbin J et al: Coadministration of interleukin-18 and interleukin-12 induces a fatal infammatory response in mice: Critical role of natural killer cell interferon-production and STAT-mediated signal transduction. Blood (2000) 96(4):1465-1473. (Pubitemid 30658478)
107. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olague C et al: Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 22(8):1389-1397. (Pubitemid 41103620)
108. Mazzolini G, Alfaro C, Sangro B, Feijoo E, Ruiz J, Benito A, Tirapu I, Arina A, Sola J, Herraiz M, Lucena F et al: Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2005) 23(5):999-1010. (Pubitemid 46202319)
109. Mazzolini G, Prieto J, Melero I: Gene therapy of cancer with interleukin-12. Curr Pharm Des (2003) 9(24):1981-1991. (Pubitemid 37010104)
110. Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, Watkins SC, Todo S, Herberman RB, Lotze MT, Shurin MR: Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol (2002) 2(6):337-349. (Pubitemid 35265983)
111. Tatsumi T, Takehara T, Yamaguchi S, Sasakawa A, Miyagi T, Jinushi M, Sakamori R, Kohga K, Uemura A, Ohkawa K, Storkus WJ et al: Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Gene Ther (2007) 14(11): 863-871. (Pubitemid 46780069)
112. Komita H, Zhao X, Katakam AK, Kumar P, Kawabe M, Okada H, Braughler JM, Storkus WJ: Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther (2009) 16(12):883-891.
113. Kumar P KA: RheoSwitch system: A highly sensitive ecdysone receptor-based gene regulation system induced by synthetic small-molecule ligands. In: Gene Transfer: Delivery and Expression of DNA and RNA. Friedmann T, Rossi JJ (Eds), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (2007):643-651.
114. Knippertz I, Hesse A, Schunder T, Kampgen E, Brenner MK, Schuler G, Steinkasserer A, Nettelbeck DM: Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-γ. J Immunother (2009) 32(5):524-538.
115. Tuettenberg A, Fondel S, Steinbrink K, Enk AH, Jonuleit H: CD40 signalling induces IL-10-producing, tolerogenic dendritic cells. Exp Dermatol 19(1):44-53.
116. Rossi D, Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol (2000) 18:217-242.
117. Riedl K, Baratelli F, Batra RK, Yang SC, Luo J, Escuadro B, Figlin R, Strieter R, Sharma S, Dubinett S: Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer (2003) 2:35.
118. Kirk CJ, Hartigan-O'Connor D, Mule JJ: The dynamics of the T-cell antitumor response: Chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res (2001) 61(24):8794-8802. (Pubitemid 34013893)
119. Mule JJ: Dendritic cell-based vaccines for pancreatic cancer and melanoma. Ann N Y Acad Sci (2009) 1174:33-40.
120. Rea D, Havenga MJ, van Den Assem M, Sutmuller RP, Lemckert A, Hoeben RC, Bout A, Melief CJ, Offringa R: Highly effcient transduction of human monocyte-derived dendritic cells with subgroup B fber-modifed adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol (2001) 166(8):5236-5244. (Pubitemid 32280740)
121. Sakurai F, Nakashima K, Yamaguchi T, Ichinose T, Kawabata K, Hayakawa T, Mizuguchi H: Adenovirus serotype 35 vector-induced innate immune responses in dendritic cells derived from wild-type and human CD46-transgenic mice: Comparison with a fber-substituted Ad vector containing fber proteins of Ad serotype 35. J Control Release (2010):doi:10.1016/j.jconrel.2010.08.025.
122. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, Robbins PD, Gambotto A: Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol (2004) 11(2):351-357. (Pubitemid 38380817)
123. Short JJ, Pereboev AV, Kawakami Y, Vasu C, Holterman MJ, Curiel DT: Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology (2004) 322(2):349-359. (Pubitemid 38521149)
124. de Gruijl TD, Luykx-de Bakker SA, Tillman BW, van den Eertwegh AJ, Buter J, Lougheed SM, van der Bij GJ, Safer AM, Haisma HJ, Curiel DT, Scheper RJ et
125. Hangalapura BN, Oosterhoff D, Aggarwal S, Wijnands PG, van de Ven R, Santegoets SJ, van den Tol MP, Hooijberg E, Pereboev A, van den Eertwegh AJ, Curiel DT et al: Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus. J Immunother (2010) 33(7):706-715.
126. Sapinoro R, Maguire CA, Burgess A, Dewhurst S: Enhanced transduction of dendritic cells by FcRI-targeted adenovirus vectors. J Gene Med (2007) 9(12):1033-1045. (Pubitemid 350286408)
127. Kim HS, Kim CH, Park MY, Park JS, Park HM, Sohn HJ, Kim HJ, Kim SG, Oh ST, Kim TG: Effcient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model. Immunol Lett (2010) 131(1):73-80.
128. Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, Huang XF: Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother (2009) 32(2):145-156.
129. Sarkar D, Su ZZ, Park ES, Vozhilla N, Dent P, Curiel DT, Fisher PB: A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene Ther (2008) 15(5):293-302. (Pubitemid 351508135)
130. Huang JH, Zhang SN, Choi KJ, Choi IK, Kim JH, Lee MG, Kim H, Yun CO: Therapeutic and tumor-specifc immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther (2010) 18(2):264-274.